Plus   Neg

Regeneron Pharma Announces Positive Phase 2 Results In Rare Blood Disorder

Regeneron Pharmaceuticals Inc. (REGN) announced data from the pozelimab Phase 2 clinical program in paroxysmal nocturnal hemoglobinuria or PNH, validating the weekly 800 mg subcutaneous dosing regimen, following an initial intravenous or IV loading dose. Pozelimab reduced the abnormal destruction of red blood cells, otherwise known as "hemolysis," with patients in the initial cohort achieving normal levels of a blood biomarker of elevated hemolysis called lactate dehydrogenase or LDH.

PNH is an ultra-rare, chronic, life-threatening disease where genetic mutations cause hemolysis, resulting in a range of symptoms including fatigue, shortness of breath and blood clots.

The results from initial 6-patient cohort showed pozelimab reduced lactate dehydrogenase to normal levels at week 8 in patients with paroxysmal nocturnal hemoglobinuria, utilizing a weekly subcutaneous dosing regimen.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration has granted accelerated approval to Tazverik for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. Epithelioid sarcoma is a rare sub-type of soft... STIHL recalls about 16,400 STIHL RE 90 pressure washers due to injury hazard. According to the company, the recalled pressure washer nozzle can disconnect from the spray wand when under pressure during use, posing an injury hazard. STIHL said it received seven reports of the nozzle detaching from... CVS Health Corp. launched 13 new HealthHUB locations in CVS Pharmacy stores across Philadelphia and South New Jersey. The healthcare company said it developed the HealthHUB store format to help people manage chronic conditions more conveniently and affordably. The store also features health and wellness products, clinical services and expertise.
Follow RTT